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h vitro measurements of aerosol fine particle fraction (FPF) using particle-sizing apparatus (e.g. the twin impinger, 
multi-stage liquid impingers, cascade impactors) have a key role to play in the development of new pharmaceutical 
products and in quality control. However, use of i~z vitro methodology to attempt to predict lung deposition in viva 
is of limited value due, in part, to the inability of current apparatus to mimic upper and lower airway anatomy 
satisfactorily. Estimates of FPF based on cut-off points ranging from 5-7 pm generally overestimate lung deposition 
as measured in vivo by gamma scintigraphy. We recommend that: 
1. multistage apparatus (minimum five stages) be used to characterize particle size distribution adequately, over the 
range 0.5-5.0 pm; 
2. where possible, measurements should be made at a range of rates and profiles of flow reflecting those likely to be 
generated using the inhalation device in clinical practice (including use by young and elderly patients with varying 
degrees of airflow obstruction); 
3. encouragement should be given to the further development; standardization, and validation of apparatus with a 
‘throat’ which more closely resembles the human oropharynx and larynx. 
Pharmacokinetic methods can give a good estimate of total, but not regional, lung deposition, with drugs which 
are either not absorbed via the gastrointestinal tract, or whose absorption can be blocked by co-administration of 
charcoal: thus avoiding confounding by absorption of drug substance deposited in the oropharynx and subsequently 
swallowed. Techniques which rely on evaluation of a timed fractional output of drug substance in the urine are 
susceptible to the inherent variability of rate of absorption across the respiratory epithelium. 
We recommend that consideration should be given to the further refinement and validation of PK methods which 
would more clearly identify the fractional dose deposited in the lung. 
Lung-imaging methodology, e.g. gamma scintigraphy, employing formulations radiolabelled with gamma-ray- 
emitting radionuclides such as 99mT~, can measure total lung deposition and oropharyngeal deposition, provided 
that the radiolabelling process is appropriately validated and suitable corrections are made for attenuation of 
gamma rays by body tissues. An estimate of regional lung deposition can be made by drawing ‘regions of interest’ 
on the scintigraphic image; the precision of this measure is limited by the two-dimensional (2-D) nature of most 
images which mean that there is an overlay of structures of interest (alveoli, small and large airways), which is most 
marked centrally. Three-dimensional (3-D) imaging techniques (e.g. single photon emission computed tomography, 
SPECT; and positron emission tomography, PET) have the potential to give more detailed data on regional lung 
deposition, but are currently more expensive, employ higher radiation doses, and are less well validated than 2-D 
(planar) imaging. 
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We consider that, of the available imaging modalities, planar gamma scintigraphy represents current best practice 
for the assessment of lung deposition from inhaler devices where regional differences may be important. The 
methodology should be optimized by the adoption of generally accepted standards for radiolabelling, imaging, 
attenuation correction, and interpretation. It is important that deposition in all sites (device, oropharynx, lungs, 
stomach) should be quantified. Consideration should be given to refining the concept of regions of interest to 
coincide more closely with anatomical lung structures. Statistical methods to compare the size distributions of drug 
and radiolabel in validation experiments should be developed. In the longer term it is envisaged that three- 
dimensional imaging may play a more important part in evaluating lung deposition; an optimal three-dimensional 
anatomical model of lung zones of interest needs to be developed. 
RESPIR. MED. (1999) 93, 123-133 
Introduction 
The pattern of intrapulmonary deposition of inhaled parti- 
cles is of great interest to researchers in the fields of 
inhalation toxicology, air pollution, and pharmaceutical 
science. Knowledge of the probable regional distribution of 
inhaled particles in the lung can help predict the sites of 
pathological changes due to inhaled carcinogens or toxic 
pollutants, and may assist in predicting the pharmaco- 
dynamic effects (both beneficial and adverse) of inhaled 
medications. Of particular interest to pharmaceutical scien- 
tists is the possibility of utilizing assessments of lung 
deposition to predict therapeutic equivalence of different 
inhalation devices designed to deliver the same drug sub- 
stance. Assessment of the pharmaceutical and therapeutic 
equivalence of inhaled medications was the subject of a 
British Association for Lung Research workshop held at 
the National Heart and Lung Institute, London, in 1994 
(1). The topic of lung deposition measurement was one of 
particular interest and, 4 years on, with the availability of a 
substantial amount of new data utilizing both existing and 
novel techniques, it was felt appropriate to convene a 
further expert workshop concentrating specifically on this 
subject. To this end, a number of experts on inhalation 
therapy were invited to participate, together with experts 
from the fields of respiratory physiology, inhalation toxi- 
cology, air pollution, and lung imaging, with the aims of 
1. reviewing current methodology for evaluating lung 
deposition, in order to make recommendations for current 
‘best practice’ and for future research directions and 
2. examining the relationship between deposition of drugs 
in the lungs and their clinical effects. 
Current Methodologies for Evaluating 
Particulate Lung Deposition 
Four types of methodology are currently in use for the 
evaluation of lung deposition of inhaled particles. The first 
encompasses in vitro systems which categorize the range of 
sizes of particles in an aerosol cloud, and which could be 
predictive of the probable total and regional lung deposi- 
tion pattern in vivo. The other three all attempt to measure 
in vivo lung deposition, either directly or indirectly, and 
comprise 1. methods of direct assay of drug concentration 
in lung tissue, 2. classical pharmacokinetic studies, and 
3. lung imaging methodology. 
IN VITXO PARTICLE-SIZING METHODS 
These all involve categorizing the particles in an aerosol 
cloud into ranges of size (2). A fairly arbitrary division is 
made between ‘respirable’ particles (with a mass median 
aerodynamic diameter, MMAD, below a certain cut-off 
size, typically between 5 and 7pm), which are assumed 
preferentially to reach the lung (the ‘respirable fraction’, 
RF or more accurately the ‘fine particle fraction’, FPF), 
and larger ‘non-respirable’ particles which are assumed to a 
large extent to impact on the oropharynx (whence they can 
be swallowed, potentially leading to gastrointestinal 
absorption). The simplest apparatus in use is the Twin 
Impinger, which has an angled ‘throat’ followed by two 
collecting chambers, the first of which collects the larger 
particles (including those deposited on the ‘throat’), whilst 
the particles reaching the second chamber represent the 
FPF. More sophisticated samplers (multi-stage liquid 
impingers and cascade impactors) sub-divide the particles 
further by size range - the Andersen sampler (e.g. Copley 
Instruments Ltd., Nottingham, U.K.), for example, has 
eight stages preceded by a right-angled throat. Laser-based 
sizing devices can estimate the size range of an aerosol 
cloud and are particularly useful for measuring the output 
when solutions are nebulised; however, these detect aerosol, 
not drug, and will size particles and droplets whether they 
contain drug or not. 
In vitro testing plays a key role in the development of 
novel inhaled products, and the demonstration of reproduc- 
ible FPF data is central to quality-control procedures. 
However, these in vitro methods have a number of draw- 
backs if utilized to try to predict lung deposition: the 
anatomy of the human oropharynx, larynx, and airways is 
complex, and poorly simulated by standard techniques, and 
the inhalation phase of the human respiratory cycle is also 
poorly reproduced, although an apparatus which simulates 
this more realistically has now been developed and vali- 
dated (3). Inertial deposition of aerosol particles is deter- 
mined not only by particle size but also velocity, and the 
existing apparatus is typically calibrated to operate at either 
28.3 or 60 1 min ~ ’ (partly for historical reasons: Andersen 
cascade impactors were originally developed to sample 
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environmental air at a rate of 1 ft3 mini t, equivalent to 
28.3 1 min - I). The velocity of particles released from an 
inhaler varies with the type of device (high, from a metered- 
dose inhaler, MDI; low, from a nebuliser), and in the case 
of a dry powder inhaler (DPI), is dependent on inspiratory 
effort and flow resistance of the device. Dry powder dis- 
aggregation has also been found to vary with flow accelera- 
tion. Thus the flow-rate profile chosen for in vitro measure- 
ment may not be the most appropriate for the device under 
study, if it is to be used to predict clinical lung deposition. 
Lastly, the size of liquid aerosol particles can diminish 
during their passage from the inhalation device due to 
evaporation, and hygroscopic particles may subsequently 
enlarge in the humid environment of the lung (4) behaviour 
which cannot readily be simulated by in vitro testing. In 
practice, the FPF measured by in vitro methods generally 
over-estimates the lung deposition measured using in vivo 
systems (5). Recent developments in deposition modelling 
suggest that this problem can be redressed if a more realistic 
estimate of throat deposition is used (($7) 
DIRECT ASSAY OF DRUG IN LUNG TISSUE 
The pattern of lung deposition of inhaled particles can be 
determined directly in animals by utilizing aerosols labelled 
with a dye or with radioactivity, and examining the lungs 
directly or by autoradiography after sacrifice and dissec- 
tion. However, the use of animal models for examining lung 
deposition of inhaled medications is generally of limited 
relevance to clinical practice due to significant interspecies 
differences in airway architecture (8); and patterns of respir- 
ation (frequency, tidal volume, and regional ventilation) 
(9). 
Although clearly inappropriate for the study of inhaled 
medication in humans, post-mortem studies have been 
carried out on deceased young adults with no history of 
respiratory disease to determine sites of pathological 
change in the lungs associated with deposits of carbona- 
ceous and crystalline atmospheric pollutants (10). However, 
analogous studies have been performed on patients under- 
going lung resection surgery, who were given single doses of 
inhaled medication preoperatively. Drug concentrations 
were then assayed in peripheral and central lung tissue, and 
compared with the concentrations in blood taken during 
surgery (11). 
PHARMACOKINETIC STUDIES 
Classical pharmacokinetic (PK) methodology has been 
difficult to apply to most inhaled products as the doses 
delivered are generally small (often microgram quantities) 
and the resulting plasma levels are correspondingly low, 
often below the accurate detection limits of standard assays. 
Although the recent development of more sensitive assay 
systems has made it possible to determine the PK of inhaled 
medications more accurately (12), problems exist in trying 
to relate drug plasma levels to patterns of lung deposition. 
A sizeable proportion of the plasma content of the drug 
may be due to gastrointestinal absorption of the swallowed 
fraction resulting from oropharyngeal deposition (this is 
not a problem for some agents; e.g. sodium cromoglycate 
and fluticasone propionate; which are not absorbed to any 
extent via the gastrointestinal tract). For some other 
drugs gastrointestinal absorption can be blocked by 
co-administration of activated charcoal. Where gastrointes- 
tinal absorption is excluded, systemic levels will reflect total 
lung deposition and absorption provided that no drug 
metabolism occurs locally in the lung. The serum T,,, may 
vary for different drugs due to differences in the rate of 
absorption across the lung epithelium, or to prolonged 
binding to lung receptors (11) or airway mucus. The 
charcoal-block method has been used to quantify the 
percentage of inhaled dose deposited in the lungs for 
formoterol; ipratropium bromide, budesonide, salbutamol 
and terbutaline sulphate (13) and it has been shown that 
48-h urinary recovery of inhaled terbutaline sulphate, 
measured using the charcoal-block method, correlates well 
with whole-lung deposition estimated by gamma scintigra- 
phy (14). The contribution of swallowed drug to systemic 
levels can also be allowed for if the oral bioavailability of 
the drug under test is known (15). Lastly, it has recently 
been proposed that assay of drug levels in urine collected 
over the first 30 min after administration of inhaled medi- 
cation predominantly represents lung deposition (16) 
absorption from the gastrointestinal tract being slower than 
from the lung; however, the rate of absorption across the 
lung epithelium is variable and may be affected by such 
factors as depth of inspiration and breath-holding (17); 
cigarette smoking, respiratory viral infections and other 
causes of epithelial inflammation, and this methodology is 
not yet fully accepted. Urine or plasma PK at best will 
reflect whole-lung drug deposition, and give no information 
on regional patterns of deposition. 
LUNG IMAGING 
Planar (2-D) gamma scintigraphy 
This is the conventional method currently employed for 
radioaerosol lung deposition and mucociliary clearance 
studies (18). The test formulation is radiolabelied (usually 
with a gamma-emitting isotope such as 99mtechnetium, 
99mTc) and after inhalation the thorax is scanned using a 
gamma-camera; the radioactive counts can be digitized to 
yield a two-dimensional (2-D) image encompassing the 
oropharynx, lung fields, and stomach in addition to the 
inhalation device and an exhalation filter. The lung outlines 
can be defined utilizing a ‘imKr ventilation scan or a 
transmission scan and the images superimposed to quantify 
penetration and distribution of the gamma-labelled medi- 
cation. Before this stage, the raw counts must be corrected 
to allow for a variety of potentially confounding factors 
including background radiation, image duration, depth of 
the source, and attenuation by body tissue (see Appendix). 
In some cases it is possible to incorporate a radiolabel 
directly into the drug molecule; usually this is impracticable 
and the radiolabel is incorporated in the formulation in 
association with the drug but not chemically bound to it. In 
order to validate this technique it must be shown that the 
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radiolabel is distributed in a similar fashion to the unla- 
belled drug, by in vitro particle distribution measurements. 
The main drawback to this method is its 2-D nature. 
Conventionally, the planar image of the lungs is divided 
into ‘regions of interest’ (for instance central, intermediate, 
and peripheral), with the central zone predominantly 
encompassing the larger airways and the peripheral zone 
the smaller airways and alveoli. However there will be 
considerable overlay of these anatomical structures, par- 
ticularly centrally where alveoli, bronchioles, and bronchi 
will be superimposed. Nonetheless a ‘penetration index’ 
(PI), calculated as the ratio of peripheral to central deposi- 
tion, will give a measure of the degree to which the aerosol 
has reached the smaller airways in the lung periphery; this 
index has been shown to correlate with the split between 
tracheobronchial and alveolar deposition from model 
nebulised formulations (19). 
Single photon emission computed fotnography (SPECT) 
In this technique, a radiolabelled aerosol is prepared in a 
similar manner to planar imaging, but the gamma-camera, 
instead of obtaining only anterior and/or posterior views of 
the thorax, rotates through 360” around the patient and can 
provide tomographic views in the coronal, sagittal, and 
transverse planes. Computer manipulation can provide a 
full 3-D reconstruction in a similar fashion to X-ray com- 
puted tomography (CT scanning) (20). SPECT was first 
applied to the quantification of regional lung aerosol depo- 
sition in 1989, when Phipps et al. (21) demonstrated that the 
3-D method was more sensitive in discriminating between 
large and small airway deposition of an inhaled aerosol 
than conventional planar gamma scintigraphy. More 
recently, attempts have been made to relate these 3-D 
images directly to deposition within the morphology of the 
lungs (22). Thoracic CT scans can be used to provide better 
anatomical localization of radionuclide distribution, and to 
map the attenuation of gamma emission by the thoracic 
structures, further increasing the accuracy of the technique 
(23). More recently, magnetic resonance imaging (MRI) has 
been utilized for the same purpose, instead of CT (24) since 
it does not give any additional radiation dose. 
Currently, there are several limitations to the use of 
SPECT (25). It is more costly and requires greater technical 
facility than planar imaging. It takes longer (up to 30 min), 
during which time redistribution of the radioaerosol by 
mucociliary clearance, coughing, or absorption into the 
bloodstream may occur. To avoid extra tissue attenuation 
by the arms it is necessary to keep them raised during the 
procedure, which may cause discomfort. Lastly, the amount 
of radioactive material and hence the radiation dose 
involved is some 20-fold higher than for planar imaging, 
and this is increased further if combined with CT scanning. 
This may be of particular relevance if children are to be 
studied, since procedures involving irradiation pose special 
ethical problems (26). 
Posifvon emission tomography (PET) 
This method (27) involves labelling the inhaled drug with a 
radioactive isotope which emits positrons as it decays, 
rather than single gamma rays. These positrons annihilate 
with electrons to produce two high-energy photons which 
are emitted simultaneously at 180” to each other. These are 
detected by coincidence counting and recorded as a single 
event; this method of detection permits accurate correction 
for tissue attenuation. The resulting 3-D image can be 
co-registered with an MRI or spiral CT scan of the thorax 
to give accurate delineation of regions of interest, and the 
percentage of the inhaled drug dose delivered to these 
regions can thus be determined three-dimensionally. 
The main advantage of PET is that some fundamental 
organic isotopes (e.g. “C, 150) are positron emitters, and 
these can be incorporated directly into the drug molecule by 
isotopic substitution, hence the drug itself becomes the 
radioactive tracer. However, the available range of 
positron-emitting radionuclides is limited; other disadvan- 
tages of the technique are the need for the study site to be 
located close to a cyclotron, since positron emitters gener- 
ally have short half-lives, (e.g. “C, 20 min), and the current 
high capital and running costs entailed. Also, current 
experience in using this methodology for the study of drug 
deposition patterns in the human lung is limited (28), and 
further validation is required. 
Neither PET nor SPECT offers any advantage over 
planar gamma scintigraphy or optimal PK methods for the 
quantification of total (as opposed to regional) lung 
deposition of inhaled medications. 
Discussion 
It is tempting to assume that patterns of lung deposition 
can be directly correlated with the pharmacodynamic 
effects of inhaled medication. However, this assumption 
could be over-simplistic, as for many medicines the actual 
site of action within the airways is poorly defined, and 
variations in initial regional lung deposition may be com- 
pensated for, to some extent, by redistribution mechanisms. 
Many inhaled drugs can be absorbed through the respirat- 
ory epithelium (or if swallowed, the gastrointestinal 
mucosa) and if noP metabolized, reach the lung again via 
the systemic circulation, some may also be absorbed into 
the bronchial circulation and redistributed directly within 
the lung (29), avoiding the potential for metabolism in the 
liver. The local concentration (and hence potential activity) 
of an inhaled drug will be affected by the depth of the 
airway surface liquid (ASL) (30), and drug which persists in 
the ASL (perhaps due to drug-mucus interactions) (31) 
could be redistributed from the periphery to the central 
airways by mucociliary transport. 
P2-adrenergic receptors exist throughout the airways (on 
epithelium, smooth muscle, alveoli and specialized cell 
types including Clara cells and mucus-secreting cells) (32). 
Although one might expect that the more peripherally a 
P-adrenergic aerosol penetrates, the more P-receptors 
should be occupied and stimulated, and hence the greater 
the clinical effect, in practice the total lung dose seems to be 
more important than the regional distribution within the 
lung (33). This partly reflects the fact that as one descends 
the bronchial tree, the exposed airway surface area 
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increases exponentially, and hence the local concentration 
of inhaled drug decreases rapidly. Also the physiological 
measures commonly employed to assess bronchodilator 
response (e.g. FEV,, SGAW) are dependent on dilatation 
of mid-sized, and not peripheral, airways. Lastly; marketed 
doses of inhaled ,&agonists are often close to the plateau of 
the dose-response curve, and effective bronchodilatation 
may then be achieved provided the aerosol penetrates 
anywhere within the lung - indeed one study (using fenot- 
erol) has shown an effective bronchodilator response after 
actuation into the nasal cavity (34). In order to demonstrate 
an effect of particle size (and hence regional deposition) on 
drug potency it has been found necessary to conduct studies 
using monodisperse particles at doses sufficiently low to be 
on the steep part of the dose-response curve (35). Mus- 
carinic receptors are situated predominantly in the central 
airways (36), so anticholinergic bronchodilators should also 
be clinically effective provided they can penetrate as far as 
the larger bronchi. 
In contrast, in chronic inflammatory airway disorders the 
inflammatory process is probably present throughout the 
bronchial tree, and hence inhaled anti-inflammatory agents 
(corticosteroids and possibly cromones) presumably need 
to be distributed throughout the airways to bronchiolar 
level or beyond (there is evidence of inflammatory cells in 
the alveoli of patients with nocturnal asthma) (37). Some 
inhaled medications will require very specific targeting, e.g. 
the antiviral ribavirin, used to treat bronchiolitis due to 
respiratory syncytial virus, needs to attain inhibitory con- 
centrations in the bronchioles; pentamidine (used for 
prophylaxis against Pmunzocystis carinii pneumonia) and 
some therapeutic peptides, e.g. insulin, may need to pen- 
etrate consistently to alveolar level. Clearly for these agents 
there should be considerable predictive value for efficacy 
from lung deposition studies demonstrating good periph- 
eral lung penetration. Sequential lung imaging can evaluate 
clearance of the radiolabelled drug from the lung by 
mucociliary transport (MCT); retention of insoluble radio- 
tracer at 24 h has been considered to represent deposition 
distal to the ciliated airways, where MCT does not operate, 
i.e. in the alveoli (38). Although it is now clear that a 
considerable proportion of particles retained at 24 h are 
actually in the smaller ciliated airways rather than the 
alveoli (39), nonetheless the 24 h retention should give a 
good assessment of lung deposition in the bronchioles and 
distal air spaces and could clearly be valuable in demon- 
strating that agents required to access the distal airways 
actually do so. The data currently available in patients with 
lung disease are limited. 
There have been surprisingly few studies published in 
which lung deposition and clinical effects of an inhaled 
medication have both been measured; however, there have 
been two recent comprehensive reviews of the relationship 
between in vivo measurements of airway deposition of 
inhaled bronchodilators and corticosteroids and their 
pharmacodynamic effect (40,41). These reviews related data 
from separate lung deposition and clinical efficacy studies 
with the same devices and formulations and showed that, 
significant correlations could in general be demonstrated. 
The reviews are based on published clinical studies, the 
majority performed to demonstrate equivalence between 
two inhalation devices or two drug formulations, and it is 
possible that the strength of the deposition/effect relation- 
ship is artificially enhanced as a result of publication bias 
(42). On the other hand this is probably compensated for by 
the fact that the methodology of many of the studies was 
not optimal for demonstrating such a relationship (e.g. 
bronchodilator doses may have been on the plateau of the 
dose-response curve; optimal disease control in the corti- 
costeroid studies may not have been achieved). Two recent 
studies included measurements of both clinical effect and 
lung deposition [one using the charcoal-block PK method 
(43), the other gamma scintigraphy (44)]. In the first study 
PK measurements established that a DPI delivered approxi- 
mately twice the dose of terbutaline to the lungs as an MDI, 
and that this observed difference in deposition was reflected 
in the bronchodilator response. In the second study, differ- 
ences in the rate of inhalation of sodium cromoglycate were 
associated with differences in regional lung deposition and 
the decreased penetration seen with more rapid inspiration 
was associated with reduced protection against allergen 
challenge. This latter study correlates well with previous 
work using a PK technique, showing that rapid inhalation 
of sodium cromoglycate was associated with reduced total 
lung deposition (17). 
Measurements of lung deposition of inhaled drugs may 
therefore be of value in two specific situations; 1. in dem- 
onstrating that the preparation under study reaches those 
parts of the respiratory tract where it is designed to exert its 
pharmacological effects, and 2. as part of the evaluation of 
the comparability of two inhaled products. If a study has 
sufficient statistical power, identical patterns of lung depo- 
sition should possess predictive value for therapeutic 
equivalence. However, it should be pointed out that the 
converse is not necessarily true; for some agents (e.g. 
P-agonists, anticholinergics) two different preparations 
might have identical pharmacological, effects despite differ- 
ences in regional lung deposition, for the reasons discussed 
above. Clinical trials designed to show equivalence between 
two treatments should be properly powered, and an appro- 
priate range of doses should be studied whenever possible. 
In addition to measuring end-points reflecting efficacy, it is 
important to compare systemic activity and side-effects, as 
equivalence in risks and benefits do not necessarily go 
hand-in-hand (1,45). 
Which method of evaluating lung deposition is currently 
the one of choice? I?z vitro methods are the simplest and 
cheapest, but generally over-estimate lung deposition 
measured in vivo. In vitro apparatus that can more closely 
mimic the human upper and lower airway (46) and inhala- 
tion pattern (3) are under evaluation. Although it is now 
possible to use realistic patient flows in combination with 
mathematical models to obtain a reasonable approximation 
of lung deposition, it may be necessary to develop 
validated, anatomically realistic upper airway models 
before in vitro techniques are directly predictive of lung 
deposition. Some pharmacokinetic methods can measure 
total (but not regional) lung deposition; the charcoal-block 
method has been shown to give similar values to gamma 
scintigraphy for the estimation of whole-lung deposition of 
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terbutaline (47). Scintigraphic techniques give the most 
direct measure of total and regional lung deposition in viva; 
3-D methodology shows promise for the future, but 2-D 
gamma scintigraphy is currently the optimal technique, 
provided that it is rigorously standardized and validated 
(proposed guidelines for the performance of scintigraphic 
studies are included in the Appendix). It is possible that 
estimation of regional lung deposition and peripheral pen- 
etration could be improved by refining the conventional 
‘regions of interest’ along more anatomical lines. 
Most regulatory agencies currently have extensive clinical 
testing requirements for demonstrating equivalence of new 
inhaler devices or formulations with the original product. 
Acceptance of validated measurements of lung deposition 
as a surrogate for some or all of these clinical studies would 
greatly reduce the resources required for such developments 
(48). Although such acceptance will take time it might be 
possible for the concept to be tested by, for example, 
submitting a lung deposition study to ‘bridge’ between 
clinical trial data where several dose formulations of a 
particular product (e.g. an inhaled corticosteroid) are being 
developed. 
Conclusions 
In vitro measurements of aerosol particle size distribution 
are important during technical development of new 
inhaler devices, and in quality control, but give only 
imprecise estimates of potential in vivo lung deposition. 
Measurements should be made using multistage 
apparatus to give an adequate characterization of the 
distribution of particle sizes and should, when possible, be 
carried out at flow rates relevant to clinical practice. In 
order to improve ‘entry’ conditions into particle sizing 
equipment, more work is required on the standardization 
and validation of ‘throats’ intended to simulate the 
oropharynx and larynx. 
PK methods have a role to play in assessing total lung 
deposition. Care has to be taken to exclude the potential 
component of plasma (or urine) drug concentration that 
can arise from gastrointestinal absorption following 
orophyaryngeal deposition. The charcoal-block method 
works well with a number of drugs. 
Planar gamma scintigraphy is a valuable tool for assess- 
ing total and regional lung deposition. Careful control is 
needed over radiolabelling validation, imaging, attenuation 
correction and interpretation. Three-dimensional lung 
imaging methods offer promise for specialized studies relat- 
ing deposition sites more closely to anatomical locations. 
Detailed information about drug deposition sites within 
the lung may greatly help in the design of future trials on 
clinical efficacy and particularly when this requires to be 
assessed for varying formulations or presentations of the 
same drug. Similarity of total and localized deposition 
between different products is likely to predict similarity of 
effect. The converse may not hold. For lung deposition data 
to attain their full potential value the interplay between the 
clinical efficacy and the systemic activity of the medication, 
and the deposited drug distribution within the lung, 
requires further exploration in order more clearly to define 
the relationships for each drug class and device. 
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Appendix. In Vim Lung Deposition: 
Standards for Scintigraphical Studies 
INTRODUCTION 
In scintigraphical studies conducted to determine the in vivo 
deposition pattern of an inhaled drug, the accuracy of the 
lung deposition values reported depend upon two critical 
factors: 
1. the quality of the radiolabelling method used; 
2. how the raw counts are converted into percentage depo- 
sition values, and in particular how the attenuation of 
gamma rays by different body tissues is corrected for. 
VALIDATING RADIOLABELLING METHODS 
FOR PHARMACEUTICAL AEROSOLS 
Labelling organic molecules chemically with gamma- 
emitting radionuclides is impracticable for the majority of 
inhaled drugs due to the short half-lives of suitable radio- 
isotopes, although there is some recent experience with “C 
(half-life 20 min) (27). Consequently, radiolabelling meth- 
ods involving the use of 99mTc as a surrogate marker for the 
drug have been developed. As the labelling involves a 
physical association between the drug and radiolabel, and 
not a chemical bond, the method must be validated to 
prove that the radiolabel will match the distribution of the 
drug (49). The objectives of validating a radiolabelling are 
as follows: 
1. To show that the radiolabel will act as a valid marker for 
the drug by demonstrating in vitro that the particle size 
distribution of the radiolabel matches the particle size 
distribution of the drug. 
2. To demonstrate that the labelling process does not affect 
the size distribution of the cloud generated by the 
inhaler. 
Methodology 
This is accomplished by measuring the particle size distri- 
butions (PSD) in the delivered cloud of the following: 
1. drug that has not been radiolabelled (designated 
‘unlabelled’ drug); 
2. drug that has been radiolabelled (designated ‘labelled’ 
drug) ; 
3. the radiolabel itself. 
The ‘unlabelled’ drug is measured by taking a commer- 
cial ‘off the shelf inhaler and firing a number of doses into 
an inertial cascade impactor. The PSD is+alculated from 
the mass of drug (determined by chemical arialysis) 
deposited on the mouthpiece, sampling port (throat) and 
each impaction stage. This process is then repeated using an 
inhaler that contains drug that has been radiolabelled; the 
PSD of the ‘labelled’ drug is calculated in the same manner 
as the ‘unlabelled’ drug. The PSD of the radiolabel is 
determined by quantifying the amount of radiolabel 
deposited on the mouthpiece, throat and each impaction 
stage using a gamma camera. 
While validation experiments can generally be conducted 
using relatively low amounts of radioactivity, it is import- 
ant that validation experiments are also conducted with the 
required in vivo levels of activity to ensure that scaling up 
the amount of activity used does not affect the outcome. A 
minimum of five unlabelled and five radiolabelled inhalers 
should be prepared and tested to ensure reproducibility of 
the labelling method. Validation experiments should be 
conducted for all dosage regimens and at all inhalation flow 
rates to be used in in vivo studies. 
Standards for validation of radiolabelling methods 
In attempting to standardize how radiolabelling methods 
are validated, there are three key issues that need to be 
addressed. 
Investigators need to use an inertial impactor/impinger 
that separates the aerosol into a sufficiently large number of 
fractions so that a valid judgement can be made on the 
‘quality’ of the labelling, i.e. how closely the radiolabel 
distribution matches that of the drug. 
Procedure for pressurized metered dose inhalers 
CpMDI) 
Use Method 2 of the European Pharmacopoeia (Andersen 
Cascade Impactor, ACI), operated at 28.3 1 min ~ ’ (which 
is close to the optimal flow rate for MDIs). The AC1 
fractionates the aerosol cloud into 10 stages; the throat, 
eight impaction stages and a final filter. This level of 
detail may be required to establish that the radiolabel is 
associating with the drug and not with an excipient (50). 
Procedure for dry powder inhalers (DPI) 
Use Method 1 of the European Pharmacopoeia (five stage 
High Precision Multi-Stage Liquid Impinger, HPMLI) 
operated at a flow rate which corresponds to a pressure 
drop of 4 kPa through the device and pulling 4 1 air through 
the device. 
Presentation of data 
The PSDs of unlabelled drug, labelled drug and radiolabei 
have been presented in different ways by different investi- 
gators. Examples of how the validation data have been 
expressed include: 
1. % distribution of metered or delivered dose; 
2. % distribution on the stages of the Impactor alone; 
3. comparison of mass median aerodynamic diameters 
(MMADs); 
4. cumulative size distributions; 
5. comparison of fine particle fractions (FPFs) alone; 
6. ratio of radiolabel to drug in fractions smaller and larger 
than FPF; 
7. comparison of labelled drug and radiolabel only, using 
one of above methods. 
The problem with many of these methods is that mis- 
matches between the drug and radiolabel may be obscured. 
These mismatches may affect the accuracy of the irz viva 
data obtained. 
The following criteria are proposed for judging the 
validity of labelling. 
1. Express the PSDs of unlabelled drug, labelled drug and 
radiolabel as percentages of the delivered dose. 
2. An indication of the amount of drug (both unlabelled 
and labelled) recovered is required. One of the following 
parameters should also be shown; 
the fine particle dose (FPD, expressed as mass of 
drug); 
the amount of drug recovered expressed as a per- 
centage of the label claim; 
the average mass of drug per shot (metered or 
delivered). 
3. Summary descriptors such as FPFs or MMADs can be 
used in the text for the sake of brevity, but data must be 
provided for both drug and radiolabel on the impaction 
stages, the throat and device mouthpiece (where 
possible). 
Methods may reveal a mismatch between the drug and 
the radiolabel. The ratio of the radiolabel FPF to the 
unlabelled drug FPF has hitherto been used to define 
acceptance limits for radiolabelling methods. If this ratio is 
within the range 0.8-1.2 (based on the means of FPFs for 
five inhalers), the labelling method has been considered 
satisfactory. Although this range is broad and focused on 
FPF alone, it is diflicult, at present, to define an alternative 
which is realistically achievable. For the future; it is hoped 
that criteria for acceptance of the radiolabelling method 
which are based on the full particle size distribution will be 
developed. It is important to add that the suitability of the 
method should also be judged by reviewing the validation 
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data set out above against the clinical objectives of the 
study in which they are to be used. 
he-dose testing of study day inhalelrs 
Study day inhalers should be tested prior to dosing volun- 
teers to ensure that each inhaler prepared will produce a 
radiolabel PSD that is comparable to the validation data 
obtained. A simple impinger such as the Twin Stage 
Impinger (TSI) may be used for this QC check, provided 
that a correlation between the FPF measured by the TSI 
and the FPF measured during the validation experiments 
has been previously established. 
STUDY SUBJECTS AND INHALATION 
TECHNIQUES 
Lung deposition studies may be conducted either using 
healthy volunteers, or patients with lung disease relevant to 
the drug under evaluation. Provided the inhalation tech- 
nique is standardized, there is little evidence that the total 
lung deposition of an inhaled drug will differ between 
healthy volunteers and patients although some studies have 
shown increased particle deposition in patients with airways 
obstruction (asthma and chronic obstructive pu!monary 
disease) (51). However, marked differences in regional lung 
deposition may occur, notably a more ‘central’ deposition 
in patients with airway obstruction. Where some airways 
are blocked by mucus (e.g. patients with cystic fibrosis) 
very abnormal regional distribution patterns may be 
observed. Smokers tend to have decreased 24 h retention of 
inhaled particles (‘alveolar deposition’) which may be 
due to a combination of airway obstruction and mucus 
hypersecretion. 
Subjects of either sex are suitable for radioaerosol lung 
deposition studies, but women of childbearing potential 
should be pregnancy tested before receiving radiolabelled 
drugs, and excluded from the study if the test is positive. 
Although total lung deposition seems to be similar in men 
and women, there is some evidence that there is a greater 
deposition in the proximal airways in women compared 
with men (52). 
Studies with radiolabelled agents in children are difficult 
to justify unless some therapeutic benefit is likely to accrue 
to the child. 
Inhalation technique has a major influence on the depo- 
sition of inhaled particles and droplets, and hence should be 
carefully controlled in lung deposition studies. The subject 
should be instructed in the requisite technique, and the 
radiolabelled dose only administered once this has been 
mastered reproducibly. In order to ensure co-ordination of 
actuation and inhalation, one of the investigators (rather 
than the subject) should actuate pressurized MDIs. Of 
course: the study design may be such that a patient with 
asthma is required to use their normal inhaler technique, in 
which case instructions on technique are unnecessary. The 
inhalation manoeuvre should be recorded by connecting 
the inhaler device in series with a system which moni- 
tors inhaled flow and volume, such as a Vitalograph 
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MD1 - Compact (Vitalograph Ltd., Buckinghamshire, 
U.K.) spirometer, ideally providing the subject with visual 
feedback via a microprocessor screen; to achieve this the 
inhaler device may need to be enclosed in a container 
which maintains an airtight seal with the inhaler. Care 
must be taken to ensure that the flow rate of air through 
the inhaler has not been modified, and that the subject can 
seal his lips around the mouthpiece. Sometimes this type 
of arrangement is impracticable, and another type of 
monitoring system, such as a Respitrace respiratory 
inductance plethysmography system, will be preferable. 
Because of the inherent variability between subjects (gen- 
der, lung pathology, inhalation technique) lung deposition 
studies should ideally utilize a randomized cross-over 
design, so that each subject acts as their own control. Study 
population sizes of 8-12 subjects are generally satisfactory, 
but statistical justification for the number of subjects 
included should be provided in the study protocol. Larger 
sample sizes may be required for studies designed to show 
mathematically defined equivalence between two inhaled 
products. 
QUANTIFYING AEROSOL DEPOSITION 
Following the administration of a radiolabelled aerosol, the 




4. inhalation device (e.g. mouthpiece, actuator, spacer); 
5. exhalation filter. 
It is essential that deposition at all of these sites is quanti- 
fied accurately, to ensure that full allowance is made for 
deposition of the dose at all sites both inside and outside the 
body. In order to quantify regional lung deposition, the 
lung outlines may be defined using a ‘imKr ventilation scan 
or a transmission scan using a 99mTc flood-field source. The 
methods of Phipps et al. (21) or Newman et al. (53) can be 
used to divide the lungs into a series of regions (e.g. central, 
intermediate, and peripheral), but other ways of sub- 
dividing the lungs are also acceptable. The penetration 
index (PI) can be calculated as the counts in the peripheral 
region divided by the counts in the central region, following 
subtraction of background counts. A ‘relative penetration 
index’ can be calculated as the ratio of the PI to that of the 
krypton ventilation image; this has been shown to reduce 
intersubject variability (54). 
It is important to note that because 99mTc is a surrogate 
marker for the drug and not chemically bound to the drug, 
investigators can only seek to quantify the initial deposition 
site. Once a radiolabelled drug particle impacts on the 
airway wall, it is likely that the radiolabel and drug particle 
will become physically dissociated, and the radiolabel 
cannot be used as a marker for clearance of the drug. 
The time period over which images of the thorax are 
collected must be adjusted to take into account the nature 
of the radiopharmaceutical used. For example, 99mTc- 
pertechnetate is rapidly cleared from the lungs into the 
systemic circulation and so imaging must be complete 
within the first few minutes following administration 
otherwise deposition will be underestimated. 
Analysis of the images collected yields data in the form of 
radioactive counts, termed ‘primary’ counts. The primary 
counts are then corrected as follows, to form ‘secondary’ 
counts, involving the following: 
1. subtraction of background radiation; 
2. correction for radioactive decay, where appropriate; 
3. correction for differences in image duration, where 
appropriate; 
4. correction for the depth of the source (for lungs and 
stomach) by calculating the geometric mean of anterior 
and posterior counts. 
Gamma rays are attenuated in an exponential fashion 
as they pass through body tissues and into the gamma 
camera. The secondary counts must, therefore, be corrected 
for tissue attenuation otherwise deposition cannot be 
accurately determined. 
Tissue attenuation covvecfions 
Tissue attenuation may be corrected for by utilizing tissue 
Attenuation Correction Factors (ACFs) as follows: 
secondary counts x ACFs=final corrected counts. 
ACFs must be determined for the different anatomical 
areas imaged; the lungs, stomach and oropharynx. 
ACFs may be determined using ‘phantoms’ (55) but this 
method has been criticized as it produces a single ACF for 
all the subjects and does not allow for the anatomical 
differences between volunteers. ACFs should be determined 
for each volunteer studied. 
The following methods of determining ACFs were com- 
pared in a recent study (56). 
Body thickness technique: based upon measurements of 
body thickness and a number of assumptions about how 
different tissues attenuate gamma rays. 
Transmission scanning: involves measuring transmitted 
radiation through the area under investigation. 
Perfusion technique: injection of a known amount of a 
radiopharmaceutical that becomes trapped in the lungs. 
Sealed source: a source containing a known amount of 
activity held in the mouth. 
The results showed that ACFs for the lungs and stomach, 
but not the oropharynx, were relatively independent of the 
method used. Different combinations of the ACFs were 
then used to calculate deposition values from source data 
(secondary counts) obtained in a previous scintigraphic 
study. In addition, deposition data were calculated without 
making any corrections for attenuation. 
It was found that the deposition values obtained were 
broadly comparable, irrespective of which combination of 
ACFs were used. Failure to correct for attenuation resulted 
in lung deposition being significantly underestimated and 
device deposition being significantly overestimated. 
In the light of these findings, it can be stated that: 
1. it is essential to correct for tissue attenuation in the 
lungs, stomach and oropharynx; 
3. 
2. the body thickness technique is the simplest of these 
methods and does not subject volunteers to any 
additional radiation exposure. Transmission scans are 
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any of the methods described can be used to correct for 
attenuation, as the ACFs they produce are broadly 
comparable in terms of the deposition data they pro- 
duce. The method used to determine ACFs must be 
stated. 
It is acknowledged that the use of a single ACF for a 
easy to perform but volunteers are exposed to a slightly particular region (e.g. the lungs) may be an oversimplifica- 
higher radiation dose. Perfusion scintigraphy involves tion and future work should investigate the possibility of 
an intravenous injection and increases the radiation defining attenuation maps for each region imaged, to 
exposure of the study subjects; increase the accuracy of the quantification. 
